VEGFA and hepatocellular carcinoma: Modern systemic treatment for HCC combining anti-VEGF therapy with ICI therapy prolongs survival and is widely used in the first-line treatment of patients with HCC [5]; however, little is known about the mechanisms of response and resistance to this new treatment paradigm.